AbbVie Signs an Exclusive Research and Option to License Agreement with Sosei Heptares Targeting Inflammatory and Autoimmune Diseases

 AbbVie Signs an Exclusive Research and Option to License Agreement with Sosei Heptares Targeting Inflammatory and Autoimmune Diseases

AbbVie Signs an Exclusive Research and Option to License Agreement with Sosei Heptares Targeting Inflammatory and Autoimmune Diseases

Shots:

  • Sosei to receive ~$32M as upfront and ~$377M as option fees, development, and commercial milestones along with royalties on global sales of therapies. AbbVie to get an option to expand the collaboration up to a total of four therapies that modulate GPCR
  • Sosei will leverage its StaR technology and GPCR-focused SBDD capabilities and fund R&D activities through the completion of IND-enabling studies. AbbVie may then pay license fees to exercise its exclusive license options and will lead global development and commercialization activities
  • In 2016, Sosei collaborated with Allergan targeting Alzheimer’s and other neurological disorders for a total value of ~$3.3B. Additionally, AbbVie completed the acquisition of Allergan last month

Click here to read full press release/ article | Ref: Sosei Heptares | Image: Pharmaceutical Technology

Related News: Sosei Subsidiary Heptares and Allergan Announce Global R&D and Commercialization Partnership for Novel Treatments in Alzheimer’s and Other Neurological Disorders

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post